

Ultrasound therapy for plantar fasciitis. A double blind randomised placebo controlled trial

Submission date 12/09/2003	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 12/09/2003	Overall study status Completed	☐ Protocol
Last Edited 15/05/2012	Condition category Musculoskeletal Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Cathy Speed

Contact details
Box No 204
Department of Rheumatology
Addenbrooke's NHS Trust
Hills Road
Cambridge
United Kingdom
CB2 2QQ
+44 (0)1223 586518
cathy.speed@btinternet.com

Additional identifiers

Protocol serial number
N0544093542

Study information

Scientific Title

Study objectives

Ultrasound in plantar fasciitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Musculoskeletal Diseases: Plantar fasciitis

Interventions

To evaluate the effects of ultrasound in the treatment of plantar fasciitis. Adult subjects with plantar fasciitis will be randomised to receive either ultrasound (US) or sham (S) therapy. In the US group pulsed ultrasound will be delivered at a standardised dosage, initially five times weekly for 3 weeks, then three times weekly for 3 weeks. A single machine will be used and calibrated twice daily. The patient, assessor and treating clinician will all be blinded. Outcome measures will be recorded at 6 weeks and at 4 months from baseline. These will include an ankle and foot score and pain (primary measures), isokinetic strength of ankle plantar flexion and dorsiflexion, flexibility, inflammation (thermographic score), quality of life and general health status, a summary item of status of the injury and a follow up transition item.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

12/10/2003

Eligibility

Key inclusion criteria

200 (PROJ)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

12/10/2000

Date of final enrolment

12/10/2003

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Box No 204

Cambridge

United Kingdom

CB2 2QQ

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Other

Funder Name

Cambridge Consortium - Addenbrooke's (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2003		Yes	No